dr. garassino discusses pros with durvalumab by pd-l1 expression in stage iii nsclc
Published 5 years ago • 206 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:34
dr. garassino on the pacific trial for nsclc
-
3:50
pd-l1 expression in nsclc
-
1:36
dr. garassino discusses recent pivotal immunotherapy findings in nsclc
-
1:36
dr. garassino on increased pfs with ramucirumab combo for nsclc
-
1:12
dr. villaruz discusses pd-l1 expression in lung cancer
-
4:08
final thoughts on nsclc
-
1:00
dr. nadler discusses role of pd-l1 in squamous nsclc
-
5:14
tips for managing nsclc patients on durvalumab therapy
-
1:30
dr. garassino on erlotinib/ramucirumab versus osimertinib in egfr nsclc
-
9:27
locally advanced nsclc: operable setting
-
1:07
dr. garassino on immunotherapy in egfr-mutated lung cancer
-
1:31
dr. garassino on qol findings from the flaura study in nsclc
-
1:13
phase ii study of durvalumab for patients with nsclc
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
4:41
dr. marina garassino on tumor mutational burden and outcomes in lung cancer
-
2:03
tremelimumab and durvalumab therapy in lung cancer
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
3:48
poseidon: durvalumab /- tremelimumab chemo in 1l mnsclc
-
0:38
a day in the life of: dr tozaki, breast cancer expert | ge healthcare